新生血管性年龄相关性黄斑变性抗VEGF治疗的终生结局
结果显示约12%患者至少一眼保留驾驶视力,约15%保留阅读视力,约82%在平均剩余终生内退出治疗。
要点
- 平均剩余终生11年内,约12%患者至少一眼保留驾驶视力,约15%保留阅读视力。
- 约82%患者在平均剩余终生内退出治疗,退出前视力很可能已恶化。
- 基线年龄较轻和第一年治疗注射次数较多与更好的长期视力结局相关。
核心结论
- 抗VEGF治疗使近20%的nAMD患者在平均剩余终生内保留了有用视力。
- 超过80%的患者在平均剩余终生内停止治疗,且停止前视力可能已恶化。
- 与未干预时80%患者在发病3年内达到法定盲相比,抗VEGF治疗结局显著更优。
研究设计与样本
- 采用多状态模型分析3192例nAMD患者的真实世界队列数据,数据来自澳大利亚、新西兰和瑞士的常规眼科诊所。
主要发现
- 平均剩余终生11年时,估计12%(n=371;95%CI,345-400)的患者至少一眼保留驾驶视力。
- 平均剩余终生11年时,估计15%(n=463;95%CI,434-495)的患者至少一眼保留阅读视力。
- 平均剩余终生11年时,估计82%(n=2629;95%CI,2590-2660)的患者已退出治疗。
- 基线年龄较轻和第一年治疗注射次数较多与更好的长期视力结局相关。
临床怎么用
- 应向nAMD患者提供抗VEGF治疗,以在剩余终生内保留有用视力。
- 临床中需关注长期治疗依从性,超过80%患者可能在终生内停止治疗。
- 基线年龄较轻和第一年充分注射可能有助于改善长期视力结局。
局限性
- 原文未明确报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Neovascular age-related macular degeneration (nAMD), the largest single cause of irreversible severe vision loss in high-income countries, can now be treated with vascular endothelial growth factor (VEGF) inhibitors, but to our knowledge, no data on lifetime outcomes are available. OBJECTIVE: To determine visual acuity (VA) outcomes of anti-VEGF treatment for nAMD in both eyes for patients' remaining lifetime. DESIGN, SETTING, AND PARTICIPANTS: Multistate modeling using real-world cohort data of 3192 patients with nAMD (>67 000 visits) treated in routine eye clinics in Australia, New Zealand, and Switzerland. Data were analyzed between 2007 and 2015. EXPOSURES: Intravitreal anti-VEGF treatment at the treating physician's discretion and prospective data collection in standardized registry. MAIN OUTCOMES AND MEASURES: Visual acuity in both eyes over the remaining lifetime. RESULTS: For the mean remaining lifetime of 11 years, an estimated 12% (n = 371; 95% CI, 345-400) of the sample retained driving VA and an estimated 15% (n = 463; 95% CI, 434-495) reading VA in at least 1 eye. At that time, an estimated 82% of the sample (n = 2629; 95% CI, 2590-2660) had dropped out. Younger age at baseline and more injections during the first year of treatment were associated with better long-term outcomes. CONCLUSIONS AND RELEVANCE: Anti-VEGF treatment was associated with preserved useful visual acuity in almost 20% of patients over their average remaining lifetime. More than 80% of patients will cease treatment over that time, having likely experienced a deterioration of vision beforehand. This is a remarkable outcome compared with outcomes without intervention, which lead to legal blindness within 3 years of disease onset in 80% of those affected. These findings underline the public health necessity of providing anti-VEGF treatment to persons in need.
引用
- Finger RP, Puth MT, Schmid M, et al. Lifetime Outcomes of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration. JAMA Ophthalmol. 2020. PMID: 33057589. doi:10.1001/jamaophthalmol.2020.3989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。